SANUWAVE Health, Inc. announced today the appointment of Dr. Toni Rinow as CFO
Eden Prairie, MN, Aug. 16, 2022 (GLOBE NEWSWIRE) — Via NewMediaWire — SANUWAVE Health, Inc. (OTCPK: SNWV), a leading provider of next-generation wound care products, today announced the appointment of Dr. Toni Rinow, MBA as Chief Financial Officer (CFO).
“With current funding and recently completed SEC filings, bringing in a world-class CFO to develop the accounting and finance function is a strategic next step for SANUWAVE,” stated Kevin Richardson, CEO of SANUWAVE. “Dr. Rinow comes to us with a wealth of experience, including a strong history of driving business transformations and revenue acceleration. We believe he will add great value to the SANUWAVE team and are excited to take this next step as we move the company forward.”
Dr. Rinow is a transformational business and financial leader with over 20 years of experience and a proven track record in international corporate development. Toni specializes in guiding companies through inflection points of growth, innovation, technology convergence and business integration. She is a catalyst for growth and expansion and is known for accelerating revenue streams through acquisitions, corporate development, sales and marketing, and financing. Toni transforms data into actionable strategies and most recently served on a NASDAQ-traded wellness company that raised over $130 million in capital expansion financing and executed on acquisitions underwriting a Morgan equity portfolio Stanley.
Toni led healthcare organizations as CEO of global nuclear medicine leader Jubilant Draximage Inc and as COO of Isologic Innovative Radiopharmaceuticals. His career includes leadership roles in both public and private pharmaceutical and healthcare organizations, where he led acquisitions in Canada, Latin America, Europe, India and the US and supported the transition of biotech companies to an initial public offering . Toni has successfully facilitated the negotiation of international corporate alliances valued at over $100 million and has overseen a portfolio of life sciences investments with $400 million under management.
Dr. Rinow holds an MBA and an MSc in Accounting from McGill University, as well as a chemical engineering degree from the European Higher Institute of Chemistry ERASMUS in Strasbourg, France, and a Ph.D. in Biophysics and Chemistry from the University of Montreal. She is trained in artificial intelligence at the MIT Massachusetts Institute of Technology. Dr. Rinow believes in giving back to the community and served on the Board of Directors of several non-profit organizations.
SANUWAVE Health focuses on the research, development and commercialization of its proprietary, non-invasive, biological response activator medical systems for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.
SANUWAVE’s ENERGY FIRST Wound Care portfolio includes regenerative medicine products and product candidates that help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedics/spine, aesthetics/cosmetic and cardiac/endovascular diseases.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are therefore forward-looking. Forward-looking statements include all statements that are not statements of historical fact about the current intention, belief or expectations of the company, its directors or officers. Investors are cautioned that these forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s control. Actual results may differ materially from those projected in the forward-looking statements. Key risks, assumptions and factors that could affect operating results, performance and financial condition include risks associated with regulatory approval and commercialization of the Company’s product candidates and products, non-clinical and preclinical development activities tested, regulatory oversight, company capacity. to manage capital resources issues, competition and other factors discussed in detail in the company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.
CONTACT WITH THE MEDIA:
Senior Director of Marketing and Program Management